Clinical studies have found that USP10 is lowly expressed in liver tissue samples from NAFLD patients, and further studies have shown that USP10 inhibits proteasome-mediated degradation of SIRT6 via deubiquitination. Here, USP10 is linked to metabolic dysfunction-associated steatotic liver disease.